Latest from The Ohio State University

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the prognosis of patients with chronic lymphocytic leukemia. 
 

David O'Malley, MD, gynecologic oncologist and an assistant professor in the Department of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of rucaparib (Rubraca)

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the future treatment of patients with chronic lymphocytic leukemia (CLL).
 

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in the treatment of patients with ovarian cancer.
 

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in ovarian cancer.

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).